Abstract
and MLL rearrangement were used. Karyotyping was successful in 77% of cases. Cytogenetic study discovered abnormalities in 51% from succeeded karyotyping. FISH revealed chromosomal aberration in 62.5%. FISH confirmed all cases with clonal aberrations, observed with conventional cytogenetics. Among patients with normal karyotype, 24% were detected to have clonal aberrations by FISH. Also, FISH analysis was extremely useful to detection of alteration involving of AML1 and TEL genes. We demonstrate that interphase FISH is available to detect more prognostic important genetic abnormalities than conventional cytogenetic. Cytogenetic analysis combined with FISH produced significant improvements in the sensitivity and accuracy in identification of the of risk stratification of patients.
Keywords
References
Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6:193–203.
Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535–48.
Mrózek K, Bloomfield ?D. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. Blood. 2013;122(10):1761–9.
Plasschaert SL, Kamps WA, Vellenga E, de Vries EG, de Bont ES. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev. 2004;30(1):37–51.
Lampert R, Harbott J, Boerhardt A. Cytogenetic aspects of childhood leukemias. Klin Padiatr. 2013;225(Suppl 1):30–3.
Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003;17:700–6.
Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker- Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood.2007;109:3189–97.
Foà R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L, et al. E2APBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol. 2003;120(3):484–7.
Harrison CJ, Moorman AV, Barber KE, Broadfield ZJ, Cheung KL, Harris RL, et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol. 2005;129:520–30.
Romana SP, Le Coniat M, Berger R. t(12;21): a new recurrent translocation in acute lymphoblastic leukemia. Genes, Chromosomes Cancer. 1994;9:186–91.
Robinson HM, Martineau M, Harris RL, et al. Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia. Leukemia. 2005;19(4):564–71.
Pedersen RK, Kerndrup GB, Sørensen AG, et al. Cytogenetic aberrations in adult acute lymphoblastic leukemia: optimal technique may influence the results. Cancer Genet Cytogenet.2001;128:7–10.
Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R, et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 1999;94:4036–46.
Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23:4284–96.
Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, Wu F, et al. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene. 2005;24(28):4477–85.
Gandemer V, Auclerc MF, Perel Y, et al. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosomepositive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer. 2009; 9:1–8.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.